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This study investigated the endurance exercise-induced changes in lesser known adipokines (visfatin, 
chemerin, apelin, semaphorin 3 C) related to obesity and metabolism, and their correlations with the 
changes in the parameters of obesity and glucose homeostasis. Forty metabolically healthy obese 
young males were randomly assigned to control group (C, n = 12) or exercise group (Ex, n = 28). The 
subjects in Ex participated in a 8-week supervised endurance exercise training program, comprised of 
four sessions of treadmill running at 65–70% of VO2max per week. Serum levels of visfatin, chemerin, 
apelin, and semaphorin 3 C were significantly decreased in Ex. At baseline, apelin and semaphorin 
3 C appeared to be correlated with obesity measures, including body mass index, % total fat and 
trunk fat, and waist circumference. Exercise-induced changes in these obesity measures significantly 
correlated with the changes in chemerin and semaphorin 3 C. Basal chemerin, apelin and semaphorin 
3 C correlated with glucose homeostasis parameters, including fasting plasma glucose, fasting plasma 
insulin, homeostasis model assessment of insulin resistance and β-cell function, and quantitative 
insulin-sensitivity check index to different extents. Furthermore, the changes in apelin and semaphorin 
3 C well predicted the improvements in glycemic parameters. We suggest that semaphorin 3 C is a 
novel adipokine involved in pathophysiology of obesity and metabolism, and that it is a biomarker 
representing an exercise-induced improvement in metabolically healthy obese young males.
Obesity is a medical condition in which excess body fat accumulates to the extent that presents risks for chronic 
diseases, including Type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs)1. Although obesity is an 
important risk factor for various metabolic diseases, metabolic disturbances, such as insulin resistance (IR),  are 
not always presented in obese individuals2. For example, the prevalence of IR was relatively low and IR was not 
related to body fat mass, as evidenced by euglycemic insulin clamp results from 1,146 obese subjects3. This sug-
gests that T2DM and CVDs are not simple consequences of fat depots, and there may be other factors altering 
metabolic profiles in obese individuals. Accumulated evidence suggests that the adipose tissue is an active endo-
crine organ that secretes more than 600 bioactive adipokines4, and related studies have elucidated underlying 
mechanisms and contribution of adipose tissues to the regulation of energy homeostasis. Specific adipokines, 
such as leptin and adiponectin, are reported to be involved in the etiology of metabolic diseases, and obesity leads 
to the dysregulation of adipokine secretion; therefore, adipokines may represent the link between obesity and 
energy homeostasis5.
In a step toward understanding the biological roles of adipose tissue and its clinical relevance with metabo-
lism, a number of novel adipokines have been identified over the last decade. Among, relatively, recently iden-
tified adipokines, visfatin, chemerin, apelin, and semaphorin 3 C (SEMA3C) are reported to be associated with 
obesity and T2DM. Visfatin is an adipokine that originally was reported to play a key role in maintaining pancre-
atic β cell function through nicotinamide adenine dinucleotide (NAD) biosynthetic regulation6, and it was shown 
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to enhance glucose-stimulated insulin secretion and expression of the genes associated with pancreatic β cell 
functions in mice7. Although controversies exist regarding the relationship between visfatin and glucose home-
ostasis in humans, several cross-sectional studies have confirmed that plasma visfatin level increases in subjects 
diagnosed with obesity and T2DM8. Chemerin is an adipocyte-derived peptide which has been reported to have 
auto/paracrine effects on adipose differentiation, as well as endocrine effects in metabolism9. It was suggested as 
a better measure for insulin sensitivity than HOMA-IR in an euglycemic insulin clamp study on males without 
metabolic syndrome10. Chemerin treatment induced glucose intolerance in obese diabetic mice11, and attenu-
ated insulin stimulated glucose uptake in primary human skeletal muscle12 and 3T3-L1 adipocytes13; therefore, 
chemerin may be an important regulating factor of glucose homeostasis. In addition, circulating chemerin levels 
appeared to be closely related to the measures of diabetes and obesity14. Another lesser known adipokine, apelin, 
appeared to be linked to obesity and glucose homeostasis15,16. Apelin was also shown to have endocrine potency, 
as it increased glucose uptake both in human adipose tissue17 and in 3T3-L1 adipocytes18. These studies suggested 
that apelin may increase to compensate for the disturbed metabolic and hormonal milieu in obesity or diabetes. 
SEMA3C, which has been recognized for its roles in cancer biology, was recently identified as an adipokine that 
is expressed and secreted from white adipose tissue from transcriptome data and secretome profiles19. Although 
there was no significant metabolic effect in isolated human adipocytes, SEMA3C appeared to be significantly cor-
related with weight changes, fat-cell hypertrophy, adipose fibrosis, and whole body insulin resistance in humans19. 
However, evidence supporting SEMA3C to be an adipokine linked to metabolism is currently limited.
Exercise training is an effective tool for preventing and improving metabolic diseases. Considering that adi-
pokines are dysregulated in obesity and exercise training has positive effects on impaired adipokine system and 
systemic metabolic homeostasis, beneficial effects of exercise are partially mediated through the changes in some 
adipokines20. Although the positive effects of exercise training on the changes in leptin and adiponectin and their 
relevance with glucose homeostasis have been reported, there may be many other adipokines that have not yet 
been investigated in this context21. In this study, we investigated the endurance exercise-induced changes in novel 
adipokines, including visfatin, chemerin, apelin, and SEMA3C, and their correlations with the changes in meta-
bolic parameters in young obese Korean males.
Results
Effects of endurance exercise program on biochemical measures. Clinical parameters at base-
line and follow-up in C and Ex are shown in Table 1. Ex showed significant reductions in all obesity measures 
(BMI, % total fat, % trunk fat, and WC, all p < 0.001) and a significant increase in % lean body mass (p < 0.001) 
compared to C. FPI (p = 0.005), HOMA-IR (p = 0.007), and HOMA-β (p = 0.039) significantly decreased, while 
QUICKI (p < 0.001) significantly improved in Ex. LDL-C was significantly reduced in Ex (p = 0.001). In addition, 
Ex showed a significant decrease in systolic blood pressure (SBP) (p < 0.001). Diastolic blood pressure (DBP) in 
C significantly increased (p = 0.041), while Ex showed no change. Leptin (p < 0.001) was significantly reduced 
in Ex; while 8-week endurance exercise program decreased total adiponectin levels to near statistically signif-
icant level, it significantly increased the more biologically active high molecular weight (HMW) adiponectin4 
in Ex (p < 0.001). The novel adipokines, visfatin (39.44 ± 13.41 to 33.48 ± 12.72 ng/mL, p = 0.025), chemerin 
(145.25 ± 66.31 to 118.14 ± 48.25 ng/mL p = 0.026), apelin (684.76 ± 198.22 to 555.29 ± 183.74 pg/mL, p = 0.019), 
and SEMA3C (6.95 ± 1.15 to 5.12 ± 1.95 ng/mL p = 0.008), significantly decreased in Ex. Statistically significant 
larger changes in these adipokines compared with C were shown. The changes are shown as individual delta 
values in Fig. 1
Association between basal novel adipokines and other variables. Associations between the levels 
of novel adipokines at baseline and the parameters of anthropometry and glucose homeostasis in all subjects, 
regardless of groups, were examined (Table 2). Basal serum visfatin showed significant positive correlations with 
% trunk fat (r = 0.355, p = 0.025) and WC (r = 0.480, p = 0.002); serum apelin was positively correlated with BMI 
(r = 0.454, p = 0.003), % total fat (r = 0.345, p = 0.029), % trunk fat (r = 0.422, p = 0.007), and WC (r = 0.353, 
p = 0.025); and serum SEMA3C was positively correlated with BMI (r = 0.504, p < 0.001), % total fat (r = 0.618, 
p < 0.001), % trunk fat (r = 0.684, p < 0.001), and WC (r = 0.451, p < 0.001). However, serum chemerin did not 
demonstrate significant association with any anthropometric measures. Basal serum chemerin was correlated 
with FPI, HOMA-IR, and QUICKI (r = 0.357, p = 0.024; r = 0.341, p = 0.031; r = −0.359, p = 0.023, respectively); 
basal serum apelin was correlated with FPI, HOMA-IR, HOMA-β and QUICKI (r = 0.672, p < 0.001; r = 0.603, 
p < 0.001; r = 0.696, p < 0.001; r = −0.613, p < 0.001, respectively); and basal serum SEMA3C was correlated with 
FPG, FPI, HOMA-IR, HOMA-β and QUICKI (r = 0.311, p = 0.044; r = 0.354, p = 0.028; r = 0.578, p < 0.001; 
r = 0.371, p = 0.019; r = −0.613, p < 0.001, respectively). There was no significant association between basal serum 
visfatin and any glycemic parameters.
Associations between changes in novel adipokines and changes in other varia-
bles. Exercise-induced changes in the novel adipokines and the measures of anthropometry (Table 3) and 
glucose homeostasis (Table 4) were examined. The change in serum visfatin was significantly correlated with the 
changes in % trunk fat (β = 0.478, p = 0.010) and WC (β = 0.381, p = 0.044); the change in serum chemerin was 
significantly correlated with the changes in BMI (β = 0.476, p = 0.010), % total fat (β = 0.689, p < 0.001), % trunk 
fat (β = 0.607, p = 0.001), and WC (β = 0.424, p = 0.025); the change in serum apelin was correlated with only the 
changes in WC (β = 0.419, p = 0.027); and the change in serum SEMA3C was correlated with the changes in BMI 
(β = 0.489, p = 0.009), % total fat (β = 0.535, p = 0.006), % trunk fat (β = 0.448, p = 0.018), and WC (β = 0.478, 
p = 0.010).
In simple linear regression, the changes in serum levels of visfatin and chemerin were positively associated 
with a change in FPG (β = 0.485, p = 0.009; β = 0.484, p = 0.009, respectively); these associations to the changes in 
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Control Group Exercise Group
Baseline Follow-Up p Baseline Follow-Up p pa pΔ
Age (yr) 27.08 ± 2.78 25.04 ± 3.01 0.050
Weight (Kg) 85.94 ± 7.54 86.41 ± 8.37 0.341 89.59 ± 9.52 85.51 ± 9.07 <0.001# 0.388 <0.001
BMI 28.23 ± 2.28 28.40 ± 2.61 0.307 28.41 ± 2.37 27.14 ± 2.47 <0.001# 0.483 <0.001
Total Fat (%) 26.52 ± 3.21 26.59 ± 3.12 0.770 27.01 ± 2.95 24.39 ± 3.37 <0.001# 0.654 <0.001
Trunk Fat (%) 28.35 ± 3.89 29.26 ± 3.73 0.023* 28.91 ± 3.37 25.66 ± 6.07 <0.001# 0.945 <0.001
WC (cm) 97.62 ± 3.88 99.77 ± 5.04 0.010* 100.58 ± 4.96 91.79 ± 5.62 <0.001# 0.312 <0.001
FPG (mg/dL) 92.67 ± 7.66 93.83 ± 4.69 0.435 90.78 ± 5.29 88.26 ± 7.79 0.076 0.160 0.112
FPI (uU/mL) 4.20 ± 3.07 5.08 ± 3.11 0.285 4.66 ± 2.96 2.67 ± 1.87 <0.001# 0.998 0.005
HOMA-IR 0.97 ± 0.76 1.21 ± 0.80 0.266 1.14 ± 1.05 0.58 ± 0.44 <0.001# 0.681 0.007
QUICKI 0.40 ± 0.04 0.39 ± 0.04 0.194 0.39 ± 0.04 0.45 ± 0.03 <0.001* 0.580 0.001
HOMA-β (%) 50.29 ± 31.04 58.15 ± 29.05 0.330 60.09 ± 33.07 42.02 ± 25.40 0.004# 0.379 0.039
2h-AUC (a.u.) 14905.83 ± 2687.66 15212.92 ± 1943.32 0.194 15014.44 ± 1733.96 14560.37 ± 2052.68 0.120 0.254 0.103
TG (mg/dL) 129.1 ± 35.64 133.25 ± 46.56 0.662 97.22 ± 37.77 86.19 ± 46.79 0.171 0.715 0.260
TC (mg/dL) 180.58 ± 14.74 181.33 ± 31.92 0.930 174.93 ± 26.85 167.30 ± 24.24 0.076 0.065 0.318
HDL-C (mg/dL) 49.4 ± 8.24 49.67 ± 9.17 0.738 47.93 ± 7.63 50.59 ± 10.17 0.078 0.778 0.435
LDL-C (mg/dL) 103.92 ± 13.73 105.42 ± 25.58 0.852 109.44 ± 25.53 97.59 ± 21.94 0.001# 0.388 0.058
SBP (mmHg) 133.33 ± 9.75 132.17 ± 9.89 0.409 130.44 ± 10.01 125.81 ± 7.47 <0.001# 0.656 0.059
DBP (mmHg) 81.67 ± 7.98 83.83 ± 6.24 0.041* 84.89 ± 4.56 84.11 ± 3.66 0.094 0.008$ 0.003
Leptin (ng/mL) 6.58 ± 2.83 6.66 ± 3.42 0.864 6.62 ± 2.65 2.68 ± 1.48 <0.001# 0.988 <0.001
TAdpn (ng/mL) 6.49 ± 2.80 5.80 ± 2.47 0.104 6.70 ± 2.66 6.03 ± 2.30 <0.001# 0.906 0.074
HMWAdpn (%) 2.68 ± 0.76 4.93 ± 5.99 0.207 2.31 ± 0.58 14.86 ± 8.53 <0.001* 0.079 <0.001
Table 1. Clinical Characteristics at Baseline and Follow-up. Values are mean ± SD; *significantly higher than 
pre-intervention within group; #significantly lower than pre-intervention within group; $significantly higher 
in Ex; ap for pre-intervention measures between groups; Δp for the changes in measures between groups; 
BMI: body mass index; WC: waist circumference; FPG: fasting plasma glucose; FPI: fasting plasma insulin; 
HOMA-IR: homeostatic model assessment for insulin resistance; QUICKI: quantitative insulin sensitivity check 
index; HOMA-β: homeostatic model assessment for beta-cell function; 2h-AUG: area under curve from 2-hour 
oral glucose tolerance test; TG: triglyceride; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; 
LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; TAdpn; 
total adiponectin; HMWAdpm: high molecular weight adiponectin.
Figure 1. Changes in novel adipokines after 8 week-endurance exercise program. Statistical significant changes 
in serum levels of (A) visfatin, (B) chemerin, (C) apelin, and (D) SEMA3C in the exercise group compared to 
the control group were observed. SEMA3C, semaphorin 3C.
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FPG were still significant after adjusting for the changes in conventional adipokines. The change in serum apelin 
was positively correlated with the changes in FPI, HOMA-IR and HOMA-β (β = 0.607, p = 0.001; β = 0.440, 
p = 0.019; β = 0.538, p = 0.003, respectively) and was negatively correlated with QUICKI (β = −0.491, p = 0.008); 
these associations remained significant after adjustment for the changes in conventional adipokines and anthro-
pometric measures. The change in serum SEMA3C was positively correlated with the changes in FPG, FPI and 
HOMA-IR (β = 0.491, p = 0.006; β = 0.611, p < 0.001; β = 0.543, p = 0.002, respectively) and was negatively corre-
lated with QUICKI (r = −0.512, p = 0.016); these associations remained significant after the adjustments for the 
changes in conventional adipokines and anthropometric measures.
Discussion
In this study, we demonstrated that our 8-week endurance exercise training program improved body com-
positions and metabolic parameters, and reduced serum levels of visfatin, chemerin, apelin, and SEMA3C. 
The changes in obesity parameters appeared to be correlated with the changes in serum chemerin and SEMA3C. 
In addition, we showed that, among four novel adipokines, exercise-induced change in serum SEMA3C inde-
pendently predicted the improvements in parameters of glucose homeostasis. This is the first study to investigate 
the exercise training-induced change in SEMA3C and its relevance to glucose homeostasis.
Visfatin was identified as an adipokine based on the findings that it is mainly produced in adipose tissue and 
its serum level increases in parallel with visceral fat in both mice and humans22. Several clinical studies reported 
that serum visfatin level correlates with body fat mass, especially the abdominal and visceral fat23,24. In line with 
these, serum visfatin in our subjects at baseline appeared to be correlated with % trunk fat and WC, which are 
efficient predictors for visceral fat25. Our endurance exercise training program significantly reduced serum vis-
fatin level, as previous studies did24,26; moreover, the changes in serum visfatin and % trunk fat and WC after the 
exercise training were significantly correlated in our subjects. These suggest that visfatin is a visceral fat-derived 
adipokine whose secretion is regulated by exercise-induced fat reduction. However, it has been suggested that 
serum visfatin level is not only determined by the extent of visceral fat, but can be stimulated by a hypergly-
cemia milieu such as Type 1 diabetes mellitus (T1DM) and T2DM8. Elevation of visfatin may be a physiologi-
cal response to increase insulin secretion in hyperglycemic environment. To support this, Lopez et al. reported 
that circulating visfatin was inversely and independently associated with insulin secretion, rather than insulin 
Visfatin 
(37.58 ± 12.51 ng/
mL)
Chemerin 
(141.83 ± 59.29 ng/
mL)
Apelin 
(0.68 ± 0.19 ng/mL)
Semaphorin 3 C 
(7.19 ± 1.78 ng/mL)
r p r p r p r p
Anthropometric Measures
BMI 0.241 0.102 0.160 0.324 0.454 0.003* 0.504 <0.001*
%Total Fat 0.224 0.165 0.145 0.372 0.345 0.029* 0.618 <0.001*
% Trunk Fat 0.355 0.025* 0.167 0.304 0.422 0.007* 0.684 <0.001*
WC 0.480 0.002* 0.130 0.424 0.353 0.025* 0.451 <0.001*
% Lean Mass 0.187 0.401 −0.098 0.698 0.163 0.299 0.024 0.852
Glucose Homeostasis Measures
FPG 0.263 0.121 0.167 0.317 0.044 0.788 0.311 0.044*
FPI 0.308 0.054 0.357 0.024* 0.672 <0.001* 0.354 0.028*
HOMA-IR 0.109 0.502 0.341 0.031* 0.603 <0.001* 0.578 <0.001*
HOMA-β 0.133 0.414 0.302 0.060 0.696 <0.001* 0.371 0.019
QUICKI −0.033 0.842 −0.359 0.023* −0.613 <0.001* -0.631 <0.001*
2h-AUC 0.164 0.333 0.204 0.226 0.102 0.549 −0.310 0.051
Table 2. Associations between Novel Adipokines and the Measures of Anthropometry, Glucose Homeostasis. 
Significantly associated with variables, p < 0.05. BMI: body mass index; WC: waist circumference; FPG: fasting 
plasma glucose; FPI: fasting plasma insulin; HOMA-IR: homeostatic model assessment for insulin resistance; 
2h-AUG: area under curve from 2 hour oral glucose tolerance test.
Δ BMI Δ %Total Fat Δ %Trunk Fat ΔWC
Δ % Lean 
Body Mass
β p β p β p β p β p
Δ Visfatin 0.149 0.397 0.360 0.061 0.478 0.010* 0.381 0.044* 0.211 0.277
Δ Chemerin 0.476 0.010* 0.689 <0.001* 0.607 0.001* 0.424 0.025* 0.160 0.332




0.489 0.009* 0.535 0.006* 0.448 0.018* 0.478 0.010* 0.150 0.384
Table 3. Correlation between the Changes in Anthropometric Measures and Novel Adipokines. *Significantly 
correlated among variables, p < 0.05. BMI: body mass index; WC: waist circumference.
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sensitivity27. In addition, Brown et al. showed that visfatin regulates insulin secretion, insulin receptor signaling, 
and mRNA expression of β cell function-associated genes, such as Ins, HNFβ, and HNF4α, in murine β-cells7. 
Our study subjects, unlike other studies8,23,24 showed no significant association with the measures of glucose 
homeostasis; this discrepancy may have resulted from the normoglycemic status of our subjects. Although there 
was an association between the changes in serum visfatin and FPG, this association became non-significant after 
adjustment for the changes in anthropometric measures or serum levels of leptin, adiponectin, and HMW adi-
ponectin, which are adipokines that have been reported to beneficially affect glucose metabolism4,5. In contrast 
to our finding, other studies reported that weight reduction by endurance exercise was associated with increased 
circulating visfatin and improved insulin sensitivity in obese diabetic patients28, and that exercise-induced change 
in visfatin appeared to be associated with the corresponding change in insulin sensitivity in old obese subjects29. 
These suggest that the effects of exercise on visfatin production and secretion may vary according to age and 
metabolic status of subjects, although serum visfatin levels did not exhibit significant correlations with gender30 
and age31. Taken together, we suggest that visfatin is an adipokine whose secretion and serum level are regulated 
by exercise-induced visceral fat reduction. However, its implication in the exercise-mediated improvement in 
glucose metabolism is not clear in metabolically healthy obese individuals.
Chemerin was originally identified as a chemotactic agent that is presented in skin32, and now it has been 
added to the list of adipokines based on the reports that white adipose tissue highly expresses chemerin along its 
functional receptor, CNKLR19,33. Current evidence suggests that chemerin plays a crucial role in adipogenesis, 
and this has been implicated in the control of adipose tissue regarding the regulation of glucose homeostasis and 
the development of obesity. Clinical studies have consistently reported that its gene expression and circulating 
levels are positively correlated with obesity parameters12,33,34. In support of this, high fat-induced obese mice35 
and genetically obese db/db mice11 also showed increased circulating chemerin levels compared to chow control 
and C57BL/6 control, respectively; adipocytes isolated from obese individuals secreted chemerin significantly 
more than those of lean individuals12. Considering that chemerin was defined as an important regulator in adi-
pocyte differentiation9,36, it can be suggested to be an adipokine involved in the pathogenesis of obesity. In our 
study, serum chemerin levels did not show significant positive correlations with any of the anthropometric meas-
ures, which may be due to the relatively narrow range of BMI and fat proportions across our subjects. However, 
serum chemerin level decreased after the training, as shown in previous studies with humans34,37,38 and mice39,40. 
The change in serum level also correlated with the changes in BMI, % total fat, % body fat, and WC. These 
suggest that chemerin is an adipokine whose secretion can be altered by exercise-induced adiposity reduction. 
Chemerin is generally elevated in T2DM patients33,34, especially in older T2DM patients41. Moreover, chemerin 
was suggested to be a better measure for insulin sensitivity than HOMA-IR in normoglycemic subjects10. Both 
glucose-stimulated insulin secretion from pancreatic β cells and insulin-stimulated glucose uptake in peripheral 
tissues are major features in the regulation of glucose tolerance. In this physiology, chemerin showed deteriorative 
Δ Visfatin Δ Chemerin Δ Apelin Δ Semaphorin 3 C
β p β p β p β p
No Adjustment
Δ FPG 0.485 0.009* 0.484 0.009* 0.098 0.621 0.491 0.006*
Δ FPI 0.167 0.396 0.075 0.706 0.607 0.001* 0.611 <0.001*
Δ HOMA-IR 0.182 0.353 0.096 0.627 0.440 0.019* 0.543 0.002*
Δ HOMA-β −0.158 0.421 −0.313 0.105 0.538 0.003* 0.370 0.049*
Δ QUICKI −0.344 0.073 −0.211 0.281 −0.491 0.008* −0.512 0.006*
Δ AUC −0.018 0.926 0.173 0.380 0.046 0.815 0.332 0.101
Adjusted for Δ in BMI, Fat. Truncal Fat, WC, Lean Body Mass
Δ FPG 0.265 0.310 0.236 0.346 .−0.071 0.755 0.405 0.039*
Δ FPI 0.154 0.521 0.265 0.313 0.542 0.007* 0.594 0.001*
Δ HOMA-IR 0.130 0.537 0.293 0.260 0.437 0.036* 0.534 0.003*
Δ HOMA-β 0.094 0.711 −0.058 0.833 0.612 0.001* 0.442 0.019*
Δ QUICKI −0.259 0.283 −0.346 0.129 −0.525 0.021* −0.435 0.036*
Δ AUC 0.084 0.806 0.171 0.495 −0.203 0.311 0.176 0.381
Adjusted for Δ in Leptin, Adiponectin, HMW Adiponectin
Δ FPG 0.287 0.270 0.416 0.038* 0.098 0.625 0.488 0.008*
Δ FPI 0.138 0.502 −0.058 0.783 0.561 0.002* 0.530 0.006*
Δ HOMA-IR 0.111 0.585 −0.008 0.967 0.367 0.049* 0.451 0.012*
Δ HOMA-β −0.104 0.629 −0.380 0.071 0.508 0.010* 0.397 0.045*
Δ QUICKI −0.322 0.107 −0.073 0.727 −0.466 0.014* −0.523 0.005*
Δ AUC 0.052 0.796 0.312 0.119 −0.285 0.205 0.256 0.322
Table 4. Correlation between the Changes in Novel Adipokines and the Glucose Homeostasis Measures. 
*Significantly correlated among variables. FPG: fasting plasma glucose; FPI: fasting plasma insulin; HOMA-IR: 
homeostatic model assessment for insulin resistance; HOMA-β: homeostatic model assessment for beta 
function; QUICKI: quantitative insulin sensitivity check index; 2h-AUG: area under curve from 2-hour oral 
glucose tolerance test; Ex: exercise group.
6Scientific RepoRtS |        (2020) 10:10005  | https://doi.org/10.1038/s41598-020-67004-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
effects on insulin sensitivity, while it enhanced insulin secretory response. For example, chemerin attenuated 
glucose uptake in skeletal muscle cells12, adipocytes13 and liver11. On the other hand, glucose stimulated insulin 
secretion in chemerin-knockout mice was attenuated36,42 while that in chemerin-transgenic mice was enhanced42. 
These suggest that elevated chemerin in those with glucose intolerance may be the compensatory consequence 
to stimulate insulin secretion. Significant positive associations with FPI and HOMA-IR and a significant negative 
association with the measure of insulin sensitivity (QUICKI) in our study also suggest that high serum chemerin 
is an unappreciated phenomenon for glucose homeostasis. Endurance exercise can reduce serum chemerin level, 
and this change may contribute to improved glycemic control34,37,38. Our endurance exercise program also signif-
icantly decreased serum chemerin level, and this change was significantly correlated with the change in FPG. This 
correlation remained significant after the adjustment for the changes in serum levels of leptin, adiponectin, and 
HMW adiponectin. Taken together, chemerin is an adipokine whose secretion is regulated by exercise induced fat 
reduction, and is somewhat associated with glycemic control in metabolically healthy obese individuals.
Apelin is a peptide that is expressed in multiple organs43 and has been recently identified as an adipokine, as 
its expression and secretion from humans and murine adipocytes have been confirmed15. Apelin, along with its 
receptor, AJP, is involved in a wide range of physiological functions, such as regulation of cardiac and vascular 
functions, fluid homeostasis and angiogenesis, by activating different G-proteins, depending on the cell type43. 
In addition, apelin–APJ system was reported to be associated with the pathophysiology of T2DM and obesity44. 
Apelin was shown to increase adipogenesis in primary human adipocytes17 and murine 3T3L1- adipocytes18. 
Both serum apelin and mRNA in adipose tissue appeared to be significantly correlated with BMI, % body fat, 
adipocyte size, and insulin sensitivity among 740 normoglycemic and diabetic subjects45. Other studies with 
small samples also reported higher serum apelin in obese diabetic individuals compared to lean normoglycemic 
controls16,46–48. Furthermore, apelin was suggested to be a biomarker that predicts T2DM incidence in men49. 
In line with these, serum apelin level, in our study, exhibited positive correlations with BMI, % total fat, % body 
fat, and WC, FPI, HOMA-IR, and HOMA-β, and a negative correlation with QUICKI. Our endurance exercise 
program significantly reduced serum apelin, as previous studies did45,50,51; this change, however, correlated only 
with the change in WC among anthropometric measures. We measured apelin-13, among its various fractions, 
which may represent the adipocyte-derived apelin as it is cleaved by subtilisin/kexin 3 (PCSK3), whose expression 
is increased in adipose tissue with obesity52, while others measured different fractions; therefore, further studies 
measuring the identical apelin fraction is warranted to investigate the effects of exercise on adipose tissue-derived 
apelin. Our results suggest that the changes in apelin by endurance exercise is not a simple consequence of 
adiposity-reduction, and that adiposity-reduction does not predict the change of apelin in metabolically healthy 
obese individuals. Exercise-induced change in apelin in our subjects appeared to be positively correlated with the 
changes in FPI, HOMA-IR, and HOMA-β, and negatively correlated with the change in QUICKI. These corre-
lations still remained significant when anthropometric measures and classic adipokines were controlled. Insulin 
increased apelin expressions in both murine and human adipocytes, whereas the lack of insulin in T1DM mice 
showed decreased apelin expressions in their adipose tissues15. These suggest that apelin in adipocytes appeared 
to be directly regulated by insulin. Considering that increased insulin level is the most common phenomenon in 
obesity and in the state of insulin resistance1, elevated serum apelin in obese or insulin-resistant individuals may 
be due to the apelin-tropic effect of insulin on adipocytes. Decreased serum insulin level following our endurance 
exercise program was attributed to lower insulin demand that matches enhanced peripheral insulin sensitivity, 
and this decrease actually contributed to the changes in HOMA-IR, HOMA-β, and QUICKI. These suggest that 
apelin can be used as an exercise-induced biomarker representing insulin sensitivity in normoglycemic obese 
individuals. However, a previous study reported a significant increment in apelin serum concentrations after 
endurance exercise intervention among aged obese T2DM male and female Caucasians53. As serum apelin was 
not shown to be affected by gender and age45, more research is needed regarding this matter.
SEMA3C is a secreted protein initially discovered for its roles in the development of nervous, cardiorespira-
tory, and renal systems, as well as in different oncogenic processes54. Mejhert et al.19 has identified SEMA3C as an 
adipokine, based on the findings that it is primarily secreted from subcutaneous adipose tissues and its expres-
sion is regulated by the degree of obesity, fat-cell morphology, and weight changes. Moreover, mRNA expres-
sion of SEMA3C in adipose tissue was associated with insulin sensitivity, suggesting pathophysiological roles in 
human obesity and metabolic deterioration. In line with this, serum SEMA3C levels in our subjects appeared to 
be positively correlated with BMI, % total and trunk fat, WC, FPG, FPI, HOMA-IR, and HOMA-β, and nega-
tively correlated with QUICKI. Our endurance exercise program significantly reduced serum SEMA3C, and this 
reduction was significantly associated with the changes in the associated parameters, even after the adjustments 
for obesity measures and classic adipokines. Although a previous study showed decreased SEMA3C expression 
in white adipose tissues after weight changes by calorie-restriction or bariatric surgery19, our study is the first to 
report that exercise-induced adiposity reduction resulted in decreased serum SEMA3C, which correlated with 
improved glycemic parameters. Although the physiological effects of SEMA3C via Plexins/Neuropilins has been 
investigated extensively in cancer biology54, its roles in obesity and glucose metabolism also has been suggested. 
SEMA3C was reported to bind, specifically, with Plexin D155,56 which has been implicated in the development of 
abdominal obesity and T2DM through the regulation of ECM microenvironment57 and adipose tissue fibrosis19. 
Adipose fibrosis has been suggested as a hallmark of metabolically challenged adipocytes in diabetic state and is 
negatively associated with systematic metabolism58. SEM3C has been known to transactivate multiple receptor 
tyrosine kinases and downstreams such as phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling 
pathway, which is causally associated with obesity and glucose metabolism by promoting lipid biosynthesis and 
glucose uptake and by inhibiting lipolysis59. Based on these, SEMA3C can be suggested as a potent molecule 
which participates in the pathophysiology in obesity and metabolism. Although it is not known whether atten-
uated adipose tissue fibrosis after endurance exercise training is attributed to reduced SEMA3C expression, we 
propose that SEMA3C is a novel adipokine which level is regulated by exercise-induced adiposity reduction and 
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correlates with energy metabolism in healthy young obese males. However, more research with diverse subjects 
in different ages, gender and metabolic status is warranted to suggest SEMA3C as an adipokine representing 
exercise-induced improvements of obesity and metabolic impairment.
In this study, we comprehensively investigated the effects of 8-week endurance exercise training program 
on visfatin, chemerin, apelin, and SEMA3C and its relations to changes in the measures of obesity and glucose 
homeostasis in 40 obese young adults without metabolic derangements. Visfatin, chemerin, and apelin have been 
shown to be associated with obesity and glucose metabolism, their potentials to be used as novel biomarkers are 
somewhat inconclusive based on current evidence. Based on our results, SEMA3C seems to be a better serum 
marker to represent the exercise-induced improvements of metabolic status, as its change with endurance exercise 
training was well correlated with changes in obesity parameters and it better predicted the improvements of the 
parameters of glucose homeostasis compared to others. The limitation of our study is that we cannot determine 
whether the changes in these adipokines were due to decreased adiposity, exercise training or both. To elucidate 
this uncertainty, further studies which include both exercise and calorie-restriction groups are warranted.
Methods
Participants. Forty young sedentary males (mean age: 25.9 ± 2.3 yrs) who were diagnosed with obesity 
according to the criteria for Asians established by World Health Organization (WHO) and met the following 
criteria were included in the current study:1) subjects were weight-stable, with less than 5% of weight changing 
within 2 months before enrollment;2) subjects were sedentary and spent less than 20 minutes per day for contin-
uous, regular physical activity in the past month, and never engaged in a structured exercise-training program 
before;3) subjects did not have any history of systemic diseases, infections, smoking, and medications for meta-
bolic diseases;4) subjects were not physically disabled to undergo endurance exercise training program. Initially, 
50 subjects were randomly assigned either to the control (C, n = 20) or the exercise (Ex, n = 30) group. Four 
subjects from C were excluded as they did not show up for follow-up examination, and four subjects from C and 
two subjects from Ex were further excluded, as some of their novel adipokine results lied out of the detection 
ranges of the assay kits. In detail, SEMA3C and chemerin levels of two subjects from C and one subject from Ex 
were below the detection ranges of the assay kits, and visfatin levels of two subjects from C and one subject from 
Ex were above the detection ranges of the assay kit; accordingly, data of 40 participants (12 in C, 28 in Ex) were 
finally analyzed in this study. Characteristics of the subjects in each group at baseline and follow-up are presented 
in Table 1. This work conformed to the standards set by the 64th WMA Declaration of Helsinki, and the study 
protocol was approved by the Institutional Review Board of Yonsei University College of Medicine. All subjects 
provided their written informed consent before entering the study.
Endurance exercise training program. Before the start of an 8-week supervised endurance exercise 
training program, cardiorespiratory fıtness (VO2max) of each subject was assessed by Bruce protocol60. Subjects 
participated four exercise sessions, which comprised of treadmill running at an intensity of 65–70% VO2max to 
burn approximately 600 Kcal, per week under the provision of designated trainers. VO2max of subjects in Ex 
were measured after every eight sessions to maintain the exercise intensity throughout the program. All subjects 
maintained their habitual recreational physical activities during the study period. Subjects in C maintained their 
normal lives.
Anthropometric/blood pressure measurement. Body weight and height were measured with an elec-
tronic anthropometry measuring device (BSM370, BioSpace, Seoul, Korea) to the nearest 0.01 kg and 0.01 cm, 
respectively; and BMI was calculated as weight/height2 (kg/m2). Waist circumference (WC) was measured midway 
between the lowest rib and iliac crest in the standing position using a circumference measuring tape (SECA200, 
SECA, Hamburg, Germany). The percentages of total body fat, trunk fat, and lean body mass were measured 
by dual energy X-ray absorptiometry [(DXA); Hologic Delphi W, Bedford, MA, USA], and all DXA scans were 
analyzed with QDR software version 12.6. Blood pressure was measured by digital sphygmomanometer (EASY 
X800, Jawon Medical, Seoul, Korea) after 10-minute chair-rest.
Biochemical analyses. All blood samples were collected after an overnight fast between 7:00 and 9:00 am 
and blood sampling for follow-up analyses were taken at least 48 hours after the last exercise session. Blood sam-
ples were immediately centrifuged at 3,000 rpm for 15 min at 4 °C, and the serums were collected and stored at 
−80 °C for subsequent analyses. Fasting plasma glucose (FPG), triglyceride (TG), total cholesterol (TC), high 
density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were quantified using 
an ADVIA 1650 Chemistry System (Siemens, Tarrytown, NY, USA). Fasting plasma insulin (FPI) was measured 
by ELECSYS2010 (Roche, Indianapolis, IN, USA). Whole body insulin resistance and insulin sensitivity were 
estimated by the homeostasis model assessment of insulin resistance (HOMA-IR) index [FPI (uIU/mL) x FPG 
(mg/dL])/405] and quantitative insulin sensitivity check index (QUICKI) [1/(log(fasting insulin, uIU/mL) + log 
(fasting glucose, mg/dL))], respectively. β-cell function was estimated by the homeostasis model assessment of 
β-cell function (HOMA- β) index [(360 × FPI (uIU/mL)/FPG (mg/dL) − 63]. During a standard 75 g oral glucose 
tolerance test (OGTT), blood samples were taken at 0, 30, 60, and 120 minutes after ingestion, and the product 
of blood glucose levels and time during OGTT were expressed as glucose area under the concentration time 
curve (AUC-Glu). The serum levels of leptin (RE53151, IBL International, Hamburg, Germany), total and high 
molecular weight (HMW) adiponectin (47ADPHU-E01, ALPCO, Salem, NH, USA), chemerin (ELH-Chemerin, 
RayBiotech, Norcross, GA, USA), apelin-13 and SEMA3C (MBS037239, MBS2883689, MyBioSource, San Diego, 
CA, USA) were measured by commercially available enzyme-linked immunosorbent assay (ELISA) assay kits. 
The serum level of visfatin was measured by commercially available enzyme immunoassay (EIA) kit (EK00380, 
Phoenix Pharmaceuticals, Burlingame, CA, USA). The detection ranges for leptin, total and HMW adiponection, 
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chemerin, apelin-13, SEMA3C, and visfatin were 0.7~100 ng/mL, 0.075~4.8 ng/mL, 0.5~50 ng/mL, 1~100 ng/mL, 
0.3~10 ng/mL, and 2.3~40 ng/mL, respectively. 1:5 dilution sera were used for total and HMW adiponection, and 
chemerin measurement while 1:2 dilution serum was used for SEMA3C measurement. The concentrations of 
the assayed samples were calculated by using 4-parameter curve fits based on the determined absorbance of the 
standards of each assay kit and the samples at 450 nm. The dilution factors were multiplied for total and HMW 
adiponection, chemerin, and SEMA3C for final determinations.
Statistical analysis. All data were analyzed using Statistical Package for Social Sciences software (SPSS 
22.0 K, IBM, Seoul, Korea), and are shown as mean ± SD. Baseline comparisons between the groups were assessed 
by independent sample t-test for the variables exhibiting normal distribution, and by Mann-Whitney U test for 
those not exhibiting normal distribution. To examine the differences between variables at baseline and follow-up 
within the group, paired t-test and Wilcoxin signed-rank test were performed, as appropriate. Pearson’s corre-
lation analysis was used to evaluate the associations among baseline novel adipokines at baseline and the meas-
ures of anthropometry and glucose homeostasis. Simple linear regression and multiple linear regression analyses 
between the changes in the novel adipokines and the changes in the anthropometric measures, and multiple 
linear regression analysis between the changes in the novel adipokines and the changes in the measures of glucose 
homeostasis were performed to determine the relationship between the variables. In multiple linear regression 
analyses, the changes in glucose homeostasis parameters were used as dependent variables to determine the rel-
ative contribution of novel adipokines. To estimate the independent effect of each novel adipokines on the meas-
ures of glucose homeostasis, variables influence on glucose homeostasis, including anthropometric measures, 
leptin, total- and HMW adiponectin were adjusted. Levels of statistical significance were set at p < 0.05.
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